Newbridge Financial Services Group’s Prime Medicine PRME Stock Holding History

Newbridge Financial Services Group’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$137	Hold	45	–	–	﹤0.01%	1216
2026 Q2	$166	Hold	45	–	–	﹤0.01%	1184
2026 Q1	$157	Buy	+45	New	+$171	﹤0.01%	1137

Other funds holding PRME

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

MAM

Milestone Asset Management Pittsburgh, Pennsylvania $631M AUM 19.64% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Newbridge Financial Services Group's PRME Position: Q3 2026 in Review

Newbridge Financial Services Group held its Prime Medicine (PRME) position steady in Q3 2026 at 45 shares worth $137. The position accounts for ﹤0.01% of the portfolio, ranked #1216.

Newbridge Financial Services Group first reported a position in PRME in Q1 2026 and has held it in 3 quarters since. The position peaked at $166 in Q2 2026. 6 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

Newbridge Financial Services Group held 45 shares of Prime Medicine worth $137 as of Q3 2026.
Newbridge Financial Services Group left its Prime Medicine share count unchanged in Q3 2026.
Prime Medicine made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q3 2026, its #1216 holding.
Newbridge Financial Services Group first reported a position in Prime Medicine in Q1 2026 and has held it in 3 quarters since.
Newbridge Financial Services Group's Prime Medicine position peaked at $166 in Q2 2026.
6 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Newbridge Financial Services Group's 13F filing for Q3 2026, filed 15 Oct 2026.